Deeper understanding of processes of protein misfolding, aggregation, formation of oligomers, protofibrils, and fibrils is crucial for the development of future medicine in treatment of amyloid-related diseases. While numerous reports illuminate the field, the above processes are extremely complex, as they depend on many varying parameters, such as the peptide concentration, temperature, pH, presence of metal ions, lipids, and organic solvents. Different mechanisms of amyloid fibril formation have been proposed, but the process of the oligomer−to−fibril transition is the least agreed upon. Our studies of a number of amyloidogenic proteins and peptides (insulin, Aβ peptides, the Bgl2 protein from the yeast cell wall), as well as their amyloidogenic fragments, have allowed us to propose a model of the fibril structure generation. We have found that the main building block of fibrils of any morphology is a ring-like oligomer. The varying models of interaction of ring oligomers with each other revealed in our studies make it possible to explain their polymorphism. Crucially, the amino acid sequence determines the oligomer structure for the given protein/peptide.
JanA, AdolfssonO, AllamanI, BuccarelloA-L, MagistrettiPJ, PfeiferA, MuhsA, LashuelHA (2011) Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem286, 8585–8596.
2.
StroudJC, LiuC, TengPK, EisenbergD (2012) Toxic fibrillar oligomers of amyloid-β have cross-β structure. Proc Natl Acad Sci U S A109, 7717–7722.
3.
HongS, OstaszewskiBL, YangT, O’MalleyTT, JinM, YanagisawaK, LiS, BartelsT, SelkoeDJ (2014) Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron82, 308–319.
4.
JinM, SelkoeDJ (2015) Systematic analysis of time-dependent neural effects of soluble amyloid β oligomers in culture and in vivo: Prevention by scyllo-inositol. Neurobiol Dis82, 152–163.
5.
BreydoL, KurouskiD, RasoolS, MiltonS, WuJW, UverskyVN, LednevIK, GlabeCG (2016) Structural differences between amyloid beta oligomers. Biochem Biophys Res Commun477, 700–705.
6.
KreutzerAG, HamzaIL, SpencerRK, NowickJS (2016) X-ray crystallographic structures of a trimer, dodecamer, and annular pore formed by an Aβ17-36 β-hairpin. J Am Chem Soc138, 4634–4642.
7.
TruexNL, NowickJS (2016) Coassembly of peptides derived from β-sheet regions of β-amyloid. J Am Chem Soc138, 13891–13900.
8.
TruexNL, WangY, NowickJS (2016) Assembly of peptides derived from β-sheet regions of β-amyloid. J Am Chem Soc138, 13882–13890.
9.
ZempelH, ThiesE, MandelkowE, MandelkowE-M (2010) Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci30, 11938–11950.
10.
JinM, ShepardsonN, YangT, ChenG, WalshD, SelkoeDJ (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A108, 5819–5824.
11.
ZempelH, LuedtkeJ, KumarY, BiernatJ, DawsonH, MandelkowE, MandelkowE-M (2013) Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J32, 2920–2937.
12.
HaydenEY, TeplowDB (2013) Amyloid β-protein oligomers and Alzheimer’s disease. Alzheimers Res Ther5, 60.
13.
GoureWF, KrafftGA, JerecicJ, HeftiF (2014) Targeting the proper amyloid-beta neuronal toxins: A path forward for Alzheimer’s disease immunotherapeutics. Alzheimers Res Ther6, 42.
14.
ViolaKL, KleinWL (2015) Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (Berl.)129, 183–206.
VestergaardB, GroenningM, RoessleM, KastrupJS, van de WeertM, FlinkJM, FrokjaerS, GajhedeM, SvergunDI (2007) A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils. PLoS Biol5, e134.
22.
MeislG, YangX, HellstrandE, FrohmB, KirkegaardJB, CohenSIA, DobsonCM, LinseS, KnowlesTPJ (2014) Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides. Proc Natl Acad Sci U S A111, 9384–9389.
GoldsburyCS, WirtzS, MüllerSA, SunderjiS, WickiP, AebiU, FreyP (2000) Studies on the in vitro assembly of a beta 1-40: Implications for the search for a beta fibril formation inhibitors. J Struct Biol130, 217–231.
26.
BendittEP, EriksenN (1966) Amyloid. 3. A protein related to the subunit structure of human amyloid fibrils. Proc Natl Acad Sci U S A55, 308–316.
27.
PerutzMF, FinchJT, BerrimanJ, LeskA (2002) Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci U S A99, 5591–5595.
28.
QuistA, DoudevskiI, LinH, AzimovaR, NgD, FrangioneB, KaganB, GhisoJ, LalR (2005) Amyloid ion channels: A common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A102, 10427–10432.
29.
NielsenEH, NyboM, SvehagSE (1999) Electron microscopy of prefibrillar structures and amyloid fibrils. Methods Enzymol309, 491–496.
30.
BhakG, LeeJ-H, HahnJ-S, PaikSR (2009) Granular assembly of alpha-synuclein leading to the accelerated amyloid fibril formation with shear stress. PLoS One4, e4177.
KumarS, UdgaonkarJB (2009) Conformational conversion may precede or follow aggregate elongation on alternative pathways of amyloid protofibril formation. J Mol Biol385, 1266–1276.
33.
MorrisAM, WatzkyMA, FinkeRG (2009) Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature. Biochim Biophys Acta1794, 375–397.
JeongJS, AnsaloniA, MezzengaR, LashuelHA, DietlerG (2013) Novel mechanistic insight into the molecular basis of amyloid polymorphism and secondary nucleation during amyloid formation. J Mol Biol425, 1765–1781.
36.
DovidchenkoNV, GlyakinaAV, SelivanovaOM, GrigorashviliEI, SuvorinaMY, DzhusUF, MikhailinaAO, ShiliaevNG, MarchenkovVV, SurinAK, GalzitskayaOV (2016) One of the possible mechanisms of amyloid fibrils formation based on the sizes of primary and secondary folding nuclei of Aβ40 and Aβ42. J Struct Biol194, 404–414.
37.
GrigorashviliEI, SelivanovaOM, DovidchenkoNV, DzhusUF, MikhailinaAO, SuvorinaMY, MarchenkovVV, SurinAK, GalzitskayaOV (2016) Determination of size of folding nuclei of fibrils formed from recombinant Aβ(1-40) peptide. Biochemistry (Mosc)81, 538–547.
38.
SelivanovaOM, SurinAK, MarchenkovVV, DzhusUF, GrigorashviliEI, SuvorinaMY, GlyakinaAV, DovidchenkoNV, GalzitskayaOV (2016) The mechanism underlying amyloid polymorphism is opened for Alzheimer’s disease amyloid-β peptide. J Alzheimers Dis54, 821–830.
39.
SelivanovaOM, SuvorinaMY, SurinAK, DovidchenkoNV, GalzitskayaOV (2017) Insulin and lispro insulin: What is common and different in their behavior?Curr Protein Pept Sci18, 57–64.
40.
SelivanovaOM, GlyakinaAV, GorbunovaEY, MustaevaLG, SuvorinaMY, GrigorashviliEI, NikulinAD, DovidchenkoNV, RekstinaVV, KalebinaTS, SurinAK, GalzitskayaOV (2016) Structural model of amyloid fibrils for amyloidogenic peptide from Bgl2p–glucantransferase of S. cerevisiae cell wall and its modifying analog. New morphology of amyloid fibrils. Biochim Biophys Acta1864, 1489–1499.
41.
LashuelHA, HartleyDM, PetreBM, WallJS, SimonMN, WalzT, LansburyPT (2003) Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol332, 795–808.
42.
JansenR, DzwolakW, WinterR (2005) Amyloidogenic self-assembly of insulin aggregates probed by high resolution atomic force microscopy. Biophys J88, 1344–1353.
43.
DovidchenkoNV, FinkelsteinAV, GalzitskayaOV (2014) How to determine the size of folding nuclei of protofibrils from the concentration dependence of the rate and lag-time of aggregation. I. Modeling the amyloid protofibril formation. J Phys Chem B118, 1189–1197.
44.
SuvorinaMY, SelivanovaOM, GrigorashviliEI, NikulinAD, MarchenkovVV, SurinAK, GalzitskayaOV (2015) Studies of polymorphism of amyloid-β 42 peptide from different suppliers. J Alzheimers Dis47, 583–593.
45.
SurinAK, GrigorashviliEI, SuvorinaMY, SelivanovaOM, GalzitskayaOV (2016) Determination of regions involved in amyloid fibril formation for Aβ(1-40) peptide. Biochemistry (Mosc)81, 762–769.
46.
GarbuzynskiySO, LobanovMY, GalzitskayaOV (2010) FoldAmyloid: A method of prediction of amyloidogenic regions from protein sequence. Bioinformatics26, 326–332.
47.
ParavastuAK, LeapmanRD, YauW-M, TyckoR (2008) Molecular structural basis for polymorphism in Alzheimer’s beta-amyloid fibrils. Proc Natl Acad Sci U S A105, 18349–18354.
LuJ-X, QiangW, YauW-M, SchwietersCD, MeredithSC, TyckoR (2013) Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue. Cell154, 1257–1268.
50.
ToyamaBH, WeissmanJS (2011) Amyloid structure: Conformational diversity and consequences. Annu Rev Biochem80, 557–585.
51.
ScheidtHA, MorgadoI, RothemundS, HusterD, FändrichM (2011) Solid-state NMR spectroscopic investigation of Aβ protofibrils: Implication of a β-sheet remodeling upon maturation into terminal amyloid fibrils. Angew Chem Int Ed50, 2837–2840.
52.
AhmedM, DavisJ, AucoinD, SatoT, AhujaS, AimotoS, ElliottJI, Van NostrandWE, SmithSO (2010) Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol17, 561–567.
53.
InouyeH, FraserPE, KirschnerDA (1993) Structure of beta-crystallite assemblies formed by Alzheimer beta-amyloid protein analogues: Analysis by x-ray diffraction. Biophys J64, 502–519.
54.
LansburyPT, CostaPR, GriffithsJM, SimonEJ, AugerM, HalversonKJ, KociskoDA, HendschZS, AshburnTT, SpencerRG (1995) Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat Struct Biol2, 990–998.
55.
PetkovaAT, BuntkowskyG, DydaF, LeapmanRD, YauW-M, TyckoR (2004) Solid state NMR reveals a pH-dependent antiparallel beta-sheet registry in fibrils formed by a beta-amyloid peptide. J Mol Biol335, 247–260.
56.
MalinchikSB, InouyeH, SzumowskiKE, KirschnerDA (1998) Structural analysis of Alzheimer’s beta(1-40) amyloid: Protofilament assembly of tubular fibrils. Biophys J74, 537–545.
KirschnerDA, InouyeH, DuffyLK, SinclairA, LindM, SelkoeDJ (1987) Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A84, 6953–6957.
61.
BurkeMJ, RougvieMA (1972) Cross- protein structures. I. Insulin fibrils. Biochemistry (Mosc.)11, 2435–2439.
WältiMA, RavottiF, AraiH, GlabeCG, WallJS, BöckmannA, GüntertP, MeierBH, RiekR (2016) Atomic-resolution structure of a disease-relevant Aβ(1-42) amyloid fibril. Proc Natl Acad Sci U S A113, E4976–E4984.
64.
EconomouNJ, GiammonaMJ, DoTD, ZhengX, TeplowDB, BurattoSK, BowersMT (2016) Amyloid β-protein assembly and Alzheimer’s disease: Dodecamers of Aβ42, but not of Aβ40, seed fibril formation. J Am Chem Soc138, 1772–1775.
65.
BingerKJ, PhamCLL, WilsonLM, BaileyMF, LawrenceLJ, SchuckP, HowlettGJ (2008) Apolipoprotein C-II amyloid fibrils assemble via a reversible pathway that includes fibril breaking and rejoining. J Mol Biol376, 1116–1129.
66.
TyckoR, WicknerRB (2013) Molecular structures of amyloid and prion fibrils: Consensus versus controversy. Acc Chem Res46, 1487–1496.
AstburyWT, DickinsonS, BaileyK (1935) The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem J29, 2351–2360.1.
69.
PaulingL, CoreyRB (1953) Two rippled-sheet configurations of polypeptide chains, and a note about the pleated sheets. Proc Natl Acad Sci U S A39, 253–256.
70.
ShirahamaT, CohenAS (1967) High-resolution electron microscopic analysis of the amyloid fibril. J Cell Biol33, 679–708.
71.
QiangW, YauW-M, LuJ-X, CollingeJ, TyckoR (2017) Structural variation in amyloid-β fibrils from Alzheimer’s disease clinical subtypes. Nature541, 217–221.
72.
SelivanovaOM, GorbunovaEY, MustaevaLG, GrigorashviliEI, SuvorinaMY, SurinAK, GalzitskayaOV (2016) Peptide Aβ(16-25) forms nanofilms in the process of its aggregation. Biochemistry (Mosc)81, 755–761.
